Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 256Carcinoma, Non-Small-Cell Lung 212Ovarian Neoplasms 134Lung Neoplasms 107Esophageal Neoplasms 69Triple Negative Breast Neoplasms 64Stomach Neoplasms 58Fallopian Tube Neoplasms 56Squamous Cell Carcinoma of Head and Neck 52Neoplasm Metastasis 50Head and Neck Neoplasms 44Esophageal Squamous Cell Carcinoma 43Carcinoma, Ovarian Epithelial 42Neoplasms 36Endometrial Neoplasms 34Uterine Cervical Neoplasms 32Recurrence 29Adenocarcinoma Of Esophagus 24Adenocarcinoma of Lung 22Urinary Bladder Neoplasms 21Melanoma 20Carcinoma, Squamous Cell 19Carcinoma 18Small Cell Lung Carcinoma 17Prostatic Neoplasms 15Breast Neoplasms, Male 15Adenocarcinoma, Bronchiolo-Alveolar 13Peritoneal Neoplasms 12Inflammatory Breast Neoplasms 12Testicular Neoplasms 10

Interventions

iniparib 2Poly(ADP-ribose) Polymerase Inhibitors 2amminedichloro(2-methylpyridine)platinum(II) 1ZD4054 1Sodium Chloride 1Rituximab 1Paclitaxel 1Carboplatin 1BNT162 Vaccine 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hypersensitivity × Paclitaxel × Clear all
NCT00929162 2012-08-07

ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

AstraZeneca

Phase 2 Terminated
120 enrolled 8 charts

Hypersensitivity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡